Feb 9, 2026 · 25 min · 10 segments
US futures are lower after Friday’s rebound, with tech struggling to regain its footing following last week’s sharp software sell-off. Investors are bracing for a rescheduled jobs report on Wednesday…
Julie HymanHost
Mohamed El-ErianGuest
Adam TurnquistGuestBrooke DePalma
Brian Sozzi
First up, Eli Lilly, the pharmaceutical giant buying biotech company Orna Therapeutics for $2.4 billion in cash.
That Lilly-Orna deal will include upfront payments as well as subsequent payouts based on meeting certain milestones.
Orna's developing treatments for certain autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.
The move boosts Lilly's footprint outside of the obesity market, where, of course, it currently sells its weight loss shot, ZipBound.
Until now, the drugmaker's legal strategy focused on the way that companies like HIMS market their products.
And a reminder, just last year, the two companies had a partnership that was scrapped due to concerns on deceptive marketing.
And finally, Kendrell, shares of the information technology services infrastructure provider are plunging.
Remember I was just talking with Adam Ternquist a few moments ago about these what were once unusual huge swings in individual stocks versus after earnings? This is one of the ones I was thinking of, a 50-50.
3% decline in those Kindrel shares after the company's third quarter results missed expectations.
It also lowered its full year forecast for both adjusted EBITDA margins and adjusted pre-tax profit.
At the same time, Kindrel's CFO is departing the company amid an SEC review of its accounting practices.
Kindrel said that while it doesn't expect the review to result in a restatement or other impact to those financial statements, it will delay filing its quarterly report with the SEC.
It expects to report material weaknesses in its internal control over financial reporting for fiscal 2025 and the first three quarters of fiscal 2026.
First up, Eli Lilly, the pharmaceutical giant buying biotech company Orna Therapeutics for $2.4 billion in cash.
That Lilly-Orna deal will include upfront payments as well as subsequent payouts based on meeting certain milestones.
Orna's developing treatments for certain autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.
The move boosts Lilly's footprint outside of the obesity market, where, of course, it currently sells its weight loss shot, ZipBound.
Until now, the drugmaker's legal strategy focused on the way that companies like HIMS market their products.
And a reminder, just last year, the two companies had a partnership that was scrapped due to concerns on deceptive marketing.
And finally, Kendrell, shares of the information technology services infrastructure provider are plunging.
Remember I was just talking with Adam Ternquist a few moments ago about these what were once unusual huge swings in individual stocks versus after earnings? This is one of the ones I was thinking of, a 50-50.
3% decline in those Kindrel shares after the company's third quarter results missed expectations.
It also lowered its full year forecast for both adjusted EBITDA margins and adjusted pre-tax profit.
At the same time, Kindrel's CFO is departing the company amid an SEC review of its accounting practices.
Kindrel said that while it doesn't expect the review to result in a restatement or other impact to those financial statements, it will delay filing its quarterly report with the SEC.
It expects to report material weaknesses in its internal control over financial reporting for fiscal 2025 and the first three quarters of fiscal 2026.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.